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Background: High risk of recurrence/progression bladder tumours is treated with Bacillus Calmette-Gue´rin (BCG) immunotherapy
after complete resection of the tumour. Approximately 75% of these tumours express the uncommon carbohydrate antigen sialyl-Tn
(Tn), a surrogate biomarker of tumour aggressiveness. Such changes in the glycosylation of cell-surface proteins influence
tumour microenvironment and immune responses that may modulate treatment outcome and the course of disease. The aim
of this work is to determine the efficiency of BCG immunotherapy against tumours expressing sTn and sTn-related antigen
sialyl-6-T (s6T).
Methods: In a retrospective design, 94 tumours from patients treated with BCG were screened for sTn and s6T expression. In vitro
studies were conducted to determine the interaction of BCG with high-grade bladder cancer cell line overexpressing sTn.
Results: From the 94 cases evaluated, 36 had recurrence after BCG treatment (38.3%). Treatment outcome was influenced by age
over 65 years (HR¼ 2.668; (1.344–5.254); P¼ 0.005), maintenance schedule (HR¼ 0.480; (0.246–0.936); P¼ 0.031) and multifocallity
(HR¼ 2.065; (1.033–4.126); P¼ 0.040). sTn or s6T expression was associated with BCG response (P¼ 0.024; Po0.0001) and with
increased recurrence-free survival (P¼ 0.001). Multivariate analyses showed that sTn and/or s6T were independent predictive
markers of recurrence after BCG immunotherapy (HR¼ 0.296; (0.148–0.594); P¼ 0.001). In vitro studies demonstrated higher
adhesion and internalisation of the bacillus to cells expressing sTn, promoting cell death.
Conclusion: s6T is described for the first time in bladder tumours. Our data strongly suggest that BCG immunotherapy is efficient
against sTn- and s6T-positive tumours. Furthermore, sTn and s6T expression are independent predictive markers of BCG
treatment response and may be useful in the identification of patients who could benefit more from this immunotherapy.
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Bladder cancer is the fifth most common cancer in Western society
(van Rhijn et al, 2009), with the highest recurrence rate among
solid tumours and poor prognosis when the tumour invades the
muscularis propia (Babjuk et al, 2011). To reduce the risk of
recurrence and progression to muscle invasion, non-muscle
invasive high-grade tumours, multifocal and recurrent lesions are
submitted to intravesical instillations with live attenuated Bacillus
Calmette-Gue´rin (BCG) after complete transurethral resection of
bladder tumour (TURBT; Babjuk et al, 2011). Although the
management of the disease has significantly improved with this
therapeutics, 30–40% of the patients relapse and approximately
15% progress to muscle invasive tumours (Palou Redorta, 2006).
Predicting patients who could be best served by an alternative
treatment or early cystectomy, would avoid progression, reduce
disease charge and decrease health expenses. It is consensual that
the integration of multiple biomarkers may hold predictive value;
still such biomarker panel remains to be established (Lima et al,
2012; Zuiverloon et al, 2012).
The exact mechanism by which BCG mediates anti-bladder
cancer immunity remains elusive (Alexandroff et al, 2010).
However, the capability of the bacillus to recognise and efficiently
bind to tumour cells has a determinant role in the therapeutics
outcome (Alexandroff et al, 2010). The bacillus is then internalised
triggering tumour cell apoptosis or host adaptive immune
responses (Becich et al, 1991; Ratliff, 1992). The bacterial adhesion,
fibronectin attachment protein (FAP), was recognised as the main
factor mediating BCG attachment and internalisation by bladder
tumour cells (Sinn et al, 2008; Alexandroff et al, 2010). FAP binds
to a5b1 integrins expressed by tumour cells via a fibronectin bridge
and to be responsible for the uptake of BCG–fibronectin–integrin
complexes (Sinn et al, 2008; Alexandroff et al, 2010).
Malignant transformations may be accompanied by a premature
stop in the O-glycosylation of proteins by sialylation, originating
the sialyl-Tn (sTn, Neu5Aca2-6GalNAca-O-Ser/Thr) and sialyl-
6-T antigens (s6T, Galb1-3(Neu5Aca2-6)GalNAca-O-Ser/Thr;
Dall’Olio et al, 2012). We recently reported that approximately
75% of high-grade bladder tumours, presenting elevated prolifera-
tion indexes and high risk of recurrence/progression expressed sTn
(Ferreira et al, 2013). sTn expression enhanced the invasive
capability of bladder cancer cells and was considered a surrogate
biomarker of tumour aggressiveness (Ferreira et al, 2013). Hence,
efficient therapies to manage these tumours are needed to avoid
disease progression and poor outcomes.
sTn expression is known to interfere with cell–cell adhesion,
cell–matrix interaction, including integrin-fibronectin binding,
modulate cell morphology (Clement et al, 2004; Julien et al,
2006; Pinho et al, 2007) and immune responses (Gilewski et al,
2007; Julien et al, 2009; Takamiya et al, 2013). Thus, we
hypothesise it may modulate BCG attachment to tumour cells
and/or immune response and consequently influence BCG
immunotherapy outcome. sTn is also a biomarker of concomitant
molecular alterations that may further determine the tumour
behaviour (Ohno et al, 2006). As such, this work is devoted to
evaluating the response of sTn-positive bladder tumours to BCG
immunotherapy. The sTn structurally related antigen was also
evaluated for the first time in the context of bladder cancer.
MATERIALS AND METHODS
Patient cohort. This study was performed in a retrospective series
of 94 cases with high-risk non-muscle invasive bladder cancer.
Patients were treated with TURBT and then submitted to BCG
immunotherapy in the Portuguese Oncology Institute of Porto,
between 1998 and 2006. No second-look TURBT was performed,
although the majority of the samples had muscularis propria
tumour free. All received intravesical instillation of BCG for 6
consecutive weeks (induction BCG scheme, iBCG) and 56.4% were
submitted to maintenance BCG schedule (iBCGþmaintenance
protocol with two weekly instillations every 3 months during 2
years, mBCG). The iBCG group includes patients treated before the
European Association of Urology guidelines recommending the
mBCG (Oosterlinck et al, 2006) scheme and patients showing
significant intolerance to long BCG treatment.
The male/female sex ratio was of 78:16. The patients were
followed every 3 months for the first year, every 6 months for the
second year and every 12 months thereafter by cystoscopy and
urine cytology. Recurrence was defined as the appearance of a
tumour once the treatment has begun, with at least one tumour-
free cystoscopy and cytology in-between. These recurrences were
also available for study. The non-responders were defined as
patients submitted to BCG treatment with tumour recurrence.
Finally, recurrence-free survival (RFS) was defined as the period of
time between the beginning of treatment and recurrence or the
most recent tumour-free cystoscopy and cytology. All procedures
were performed after patient’s informed consent and approved
by the Ethics Committee of IPO-Porto. All clinicopathological
information was obtained from patients’ clinical records. All
tumour samples were revised by a pathologist, regarding 2004
WHO grading criteria.
Expression of STn in bladder tumours. Formalin-fixed paraffin-
embedded tissue sections were screened for sTn by immunohisto-
chemistry using the avidin/biotin peroxidase method, as described by
Ferreira et al (2013). sTn expression was evaluated with anti-sTn
mouse monoclonal antibody clone TKH2 (Ferreira et al, 2013). The
s6T antigen was evaluated in sTn-negative tumours using the same
antibody, after treatment with a recombinant b-(1-3)-galactosidase
from Xanthomonas campestris (R&D systems, Minneapollis, MN,
USA) for 1h at 371C. This enzyme removes the O-3-linked Gal
residues exposing the sTn antigen (Figure 1A).
Both antigens were assessed double-blindly by three indepen-
dent observers. Upon disagreement, the slides were reviewed, until
a consensus was reached. Tumours were classified as positive when
immunoreactivity of anti-sTn TKH2 antibody was observed.
Structural assignments were validated by a combination of
enzymatic treatments. For sTn, positive tissues were first treated
with a a-neuraminidase from Clostridium perfringens (Sigma-
Aldrich, St Louis, MO, USA) for 2 h at 37 1C to remove the sialic
acid and then screened for sTn expression. For s6T, positive tissues
were primarily incubated with the b-(1–3)-galactosidase, followed
by incubation with the neuraminidase. The absence or decrease in
immunoreactivity of TKH2 monoclonal antibody confirmed the
presence of these structures.
Adhesion and internalisation of BCG to bladder cancer cell line
Cell lines culture. The human bladder cancer cell line MCR and
the transduced variants of MCR (MCRnc and MCRsTnþ ) were
grown as described by Videira et al (2009). The MCRsTnþ cell line
results from the stable transduction of MCR cells with a lentivirus
expressing the coding region of the human ST6GalNAc.I gene, the
enzyme responsible by the biosynthesis of sTn (Ferreira et al,
2013). The MCRnc cell line, not expressing sTn, was used as
control (Ferreira et al, 2013).
Bacterial strain and labelling. BCG strain RIVM (Medac,
Hamburg, Germany) was used in this study. Briefly, 108 viable
BCG cells were labelled with 10mg fluorescein isothiocyanate (FITC;
Invitrogen, Carlsbad, CA, USA) in 1ml of 50mM sodium carbonate
buffer (pH 9.2) for 30min at 20 1C. The labelled bacteria (BCG-FITC)
were washed three times with PBS containing 0.05% of Tween-80
(Sigma-Aldrich) and centrifuged for 10min at 13.000 g to remove
excess FITC.
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BCG adhesion and internalisation assay. MCR cells were
plated into 24-well plates at 0.2 106 cell per well. At
confluence, cells were washed and BCG-FTIC was added to
the cultures at a ratio of 10:1 (BCG/cells). After 2, 6 or 24 h
incubation time, the cells were gently washed to remove the
excess BCG, harvested and centrifuged at 350 g for 5 min. In
order to differentiate between internalised and surface-bound
BCG, trypan blue was added to quench surface-attached
fluorescence bacteria. Flow cytometry was performed on a
FACSCalibur (BD Biosciences, San Jose, CA, USA) and data
were analysed using the Flowing v2.4 software (Turku Center for
Biotechnology, Turku, Finland).
Estimation of cell viability after exposure to BCG. The influence
of BCG treatment on MCR cell viability after the 24 h of exposure
was assessed through the visualisation of morphologic changes by
flow cytometry. Dot plots of forward-angle light scatter (FSc) vs
side-angle light scatter (SSc) of MCR cells before and after
exposure to BCG were analysed using the Flowing v2.4 software
(Turku Center for Biotechnology).
For a shorter period of time of BCG exposure (6 h), apoptotic
status of cells was evaluated by labelling with Annexin V (Sigma-
Aldrich) as indicated by manufacture instructions.
Statistical analysis. Statistical data analysis was performed with IBM
Statistical Package for Social Sciences—SPSS for Windows (version
20.0; IBM, Armonk, NY, USA). Chi-square analysis was used to
compare categorical variables. Kaplan–Meier survival curves were
used to evaluate correlation between glycans expression and RFS, log-
rank statistical test was used for curves comparison. Multiple Cox
regression analysis was used to assess the effect of both antigens on
the time to recurrence in BCG-treated patients and to adjust for
potential confounders. Non-parametric Mann–Whitney test was used
to compare the differences in the BCG attachment and internalisation
to MCRnc and MCRsTnþ cells.
RESULTS
Clinicopathological features and BCG treatment outcome.
From the 94 cases evaluated, 36 had recurrence after BCG
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Figure 1. Expression of sTn and s6T in bladder tumours. Schematic representation of a bladder tumour expressing sTn and s6T antigens (A).
Urothelial cell-surface glycoproteins present more or less elongated O-glycan chains often terminated with ABO and/or Lewis blood group
determinants (not represented). Conversely, some malignant cells express the sTn and s6T (STnþGal residue) antigens that result from a
premature stop in the biosynthesis of O-glycans (A). The sTn, but not the s6T antigen, can be recognised by mouse monoclonal antibody TKH2
(A1). The digestion of the FFPE sections with a b-(1-3)-galactosidase removes the Gal residue from s6T allowing detection by TKH2 (A2). Bladder
tumour expressing the sTn antigen (B). Bladder tumour expressing the s6T antigen but not sTn (C). The FFPE tissue was positive for sTn only after
digestion of the FFPE tissue with a b-(1-3)-galactosidase. This is the first report on s6T antigen expression in bladder tumours.
BRITISH JOURNAL OF CANCER BCG immunotherapy in STn/S6Tþ bladder tumours
2108 www.bjcancer.com |DOI:10.1038/bjc.2013.571
treatment (38.3%). The median follow-up time of the patients free
of recurrence was 68.5 months (range: 6.0–135.0) and the median
time of recurrence was 38.5 months (range: 10.0–122.0). The
median follow-up time considering all the cases under analysis was
61.0 months (range: 6.0–135.0). Table 1 summarises patients and
tumour clinicopathological features and its association with BCG
response and RFS after treatment. We found that 61.1% of the non-
responders were over 65 years old at the time of tumour resection,
whereas only 36.2% of responders were over 65 years old (P¼ 0.018).
Furthermore, patients over 65 years have approximately three-fold
increased risk of recurrence (HR¼ 2.668; (1.344–5.254); P¼ 0.005).
Moreover, it was observed a higher percentage of patients treated only
with iBCG in the non-responder group when compared with the
responder group (58.3% vs 34.5%, P¼ 0.018). Therefore, patients
treated with mBCG scheme showed a 52% reduced risk of recurrence
(HR¼ 0.480; (0.246–0.936); P¼ 0.031). It was also found that patients
with multifocal tumours had an increased risk of recurrence after
BCG treatment (HR¼ 2.065; (1.033–4.126); P¼ 0.040). No associa-
tion was found for other characteristics, such as gender, tumour stage,
grade or size, CIS presence and prior recurrence.
Expression of sTn and s6T and association with clinicopatho-
logical features. Approximately 66% of the studied bladder
tumours were sTn positive (Figure 1A and B) and in all cases
the antigen was observed in more than 5% of the tumour area.
Additionally, 10 out of 32 sTn negative cases were positive for s6T
(Figure 1C), which is structurally related to sTn. However, s6T
assumed a more diffuse expression that did not exceed 5% of the
tumour area in all cases.
The expression of sTn alone or in combination with s6T (sTn/s6T)
was associated with high-grade tumours (P¼ 0.007; P¼ 0.037
Table 2) and also with primary tumours (P¼ 0.001; P¼ 0.039).
STn and sTn/s6T as predictors of BCG treatment outcome. sTn
antigen was expressed by 74.1% of BCG responders and only by
47.2% of non-responders (P¼ 0.034; Table 3). When sTn and s6T
were evaluated together, a similar relationship was observed
(P¼ 0.0001; Table 3).
From the 94 patients included in this study, 36 had recurrences
after treatment and 75% of these tumour specimens were available
for sTn and s6T screening. All non-responders who presented sTn-
Table 1. Relation between patients clinical and tumour characteristics and response to BCG treatment and time to recurrence
Variables Total n (%) Responders n (%) Non-responders n (%) Pa HR (95% CI) Pb
Age (years)
o65 51 (54.3) 37 (63.8) 14 (38.9) 0.018 1.0
X65 43 (45.7) 21 (36.2) 22 (61.1) 2.668 (1.355–5.254) 0.005
Sex
Male 78 (83.0) 47 (81.0) 31 (86.1) 0.524 1.0
Female 16 (17.0) 11 (19.0) 5 (13.9) 0.883 (0.342–2.283) 0.798
Stage
Ta 40 (42.6) 23 (39.7) 17 (47.2) 0.471 1.0
T1 54 (57.4) 35 (60.3) 19 (52.8) 0.838 (0.435–1.613) 0.596
Grade
Low 38 (40.4) 24 (41.4) 14 (38.9) 0.843 1.0
High 56 (59.6) 34 (58.6) 22 (61.1) 1.295 (0.661–2.537) 0.450
Size (cm)
o3 62 (66.7) 38 (65.5) 24 (68.6) 0.762 1.0
X3 31(33.3) 20 (34.5) 11 (31.4) 0.787 (0.384–1.613) 0.513
Tumour number
Unifocal 51 (54.3) 30 (51.7) 13 (36.1) 0.140 1.0
Multifocal 43 (45.7) 28 (48.3) 23 (63.9) 2.065 (1.033–4.126) 0.040
CIS
No 88 (93.6) 54 (93.1) 34 (94.4) 1.000 1.0
Yes 6 (6.4) 4 (6.9) 2 (5.6) 0.783 (0.188–3.267) 0.737
Recurrence status
Primary 48 (51.0) 31 (53.4) 17 (47.2) 0.557 1.0
Recurrent 46 (49) 27 (46.6) 19 (52.8) 1.327 (0.686–2.564) 0.401
BCG schedule
iBCG 41 (43.6) 20 (34.5) 21 (58.3) 0.023 1.0
mBCG 53 (56.4) 38 (65.5) 15 (41.7) 0480 (0.246–0.936) 0.031
Abbreviations: BCG¼Bacillus Calmette-Gue´rin; CI¼ confidence interval; CIS¼Carcinoma in situ; HR¼ hazard ratio; iBCG¼ induction BCG; mBCG¼maintenance BCG.
Bold values indicate Po0.05.
aChi-square test.
bWald test.
BCG immunotherapy in STn/S6Tþ bladder tumours BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2013.571 2109
negative tumours prior treatment had sTn-negative recurrences.
From the 15 non-responder patients who had sTn-positive
tumours, 40% presented sTn-negative recurrences.
Kaplan–Meier analysis was used to evaluate if sTn with or
without s6T influenced the RFS after BCG treatment. No
differences were found regarding sTn expression alone
(Figure 2A). However, when sTn and s6T were considered
together, significant differences were found (P¼ 0.001;
Figure 2B). Patients with sTn/s6T-positive tumours had higher
RFS than negative tumours (100.1 vs 63.2 months).
A Cox regression analysis, adjusted to age, tumour number and
treatment scheme, was performed to assess the individual effect of
these antigens in recurrence after BCG. Patients with sTn-positive
tumours presented a trend to a lower-risk recurrence after BCG
(HR¼ 0.544; 95% CI: (0.275–1.076); P¼ 0.080; Table 4). Likewise,
cases positive for sTn/S6T showed a significant lower risk of
recurrence (HR¼ 0.296; 95% CI: (0.148–0.594); P¼ 0.001).
BCG interaction with MCRsTnþ cell line. To evaluate the
affinity of BCG for cells expressing sTn, we set up in vitro assays
with MCRnc and MCRsTnþ cell lines, two genetically modified
variants of the original MCR bladder cancer cell line. MCRnc cells
Table 2. Association between sTn and s6T antigens and clinicopathological characteristics
sTn sTnþ s6T
Variables Negative n (%) Positive n (%) Pa Negative n (%) Positive n (%) Pa
Age (years)
o65 21 (65.6) 30 (48.4) 0.112 13 (59.1) 38 (52.8) 0.603
X65 11 (34.4) 32 (51.6) 9 (40.9) 34 (47.2)
Sex
Male 27 (84.4) 51 (86.1) 0.796 17 (77.3) 61 (84.7) 0.517
Female 5 (15.6) 11 (17.7) 5 (22.7) 11 (15.3)
Stage
Ta 16 (50.0) 24 (38.7) 0.294 10 (45.5) 30 (41.7) 0.753
T1 16 (50.0) 38 (61.3) 12 (54.5) 42 (58.3)
Grade
Low 19 (59.4) 19 (30.6) 0.007 13 (59.1) 25 (34.7) 0.042
High 13 (40.6) 43 (69.4) 9 (40.9) 47 (65.3)
Size (cm)
o3 23 (74.2) 39 (62.9) 0.276 16 (76.2) 46 (63.9) 0.431
X3 8 (25.8) 23 (37.1) 5 (23.8) 26 (36.1)
Tumour number
Unifocal 12 (37.5) 13 (50.0) 0.249 7 (31.8) 36 (50.0) 0.134
Multifocal 20 (62.5) 31 (50.0) 15 (68.2) 36 (50.0)
CIS
No 29 (90.6) 59 (95.2) 0.406 19 (86.4) 69 (95.4) 0.112
Yes 3 (9.4) 3 (4.8) 3 (13.6) 3 (4.2)
Recurrence status
Primary 9 (28.1) 39 (62.9) 0.001 7 (31.8) 41 (56.9) 0.039
Recurrent 23 (71.9) 19 (37.1) 15 (68.2) 31 (43.1)
BCG schedule
iBCG 14 (43.8) 27 (43.5) 0.985 11 (50.0) 30 (41.7) 0.490
mBCG 18 (56.2) 35 (56.5) 11 (50.0) 42 (58.3)
Abbreviations: BCG¼Bacillus Calmette-Gue´rin; iBCG¼ induction BCG; CIS¼Carcinoma in situ; mBCG¼maintenance BCG.
Bold values indicate Po0.05.
aChi-square test.
Table 3. STn and sTn/s6T frequencies and risk of recurrence after BCG
therapy
Responders n (%) Non-responders n (%) P valuea
sTn
Negative 15 (25.9) 17 (47.2)
Positive 43 (74.1) 19 (52.8) 0.034
sTn and/or s6T
Negative 6 (10.5) 16 (43.2)
Positive 51 (89.5) 21 (56.8) 0.0001
Abbreviation: BCG¼Bacillus Calmette-Gue´rin.
aChi-square test.
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were transduced with an empty vector and MCRsTnþ with the
cDNA coding for the ST6GalNAc.I sialyltransferase. The pheno-
type of these transduced variants was previously described by
Ferreira et al (2013). MCRsTnþ presents a continuous and stable
expression of the antigen sTn, whereas the MCRnc does not as
shown in Supplementary Figure 1 (in the supplementary section).
MCRsTnþ and its negative control MCRnc where then treated
with BCG. Fluorescent-labelled BCG was internalised significantly
over time, with a significant higher internalisation after 6 h incubation,
when comparing with 2h incubation (Figure 3A). Interestingly, after
6 h, MCRsTnþ cells showed a tendency to internalise higher amounts
of BCG than MCRnc cells (Figure 4A and B). Small amounts of BCG
are internalised, resulting in small shifts of FITC fluorescence of the
cells after internalisation (Figure 4B).
We then evaluated apoptosis status in MCR cells after 6 h of
BCG challenging, using Annexin V an earlier labelling marker for
cells undergoing apoptosis. It was observed a consistent tendency
for a higher cell death in MCRsTnþ after BCG challenging (higher
Annexin V labelling—MFIMCRnc¼ 2560) compared with MCRnc
cells (MFIMCRsTnþ ¼ 2640). In addition, a population of cells
presenting stronger Annexin V labelling was also observed after 6 h
BCG, which was higher (7%) in MCRsTnþ cell than MCRnc (4%;
Figure 4A). After a longer period of BCG challenging (24 h),
MCRsTnþ cells significantly decreased their size and granularity
(80% of FSClowSSClow), which is usually typical of a rupture of
plasma membrane and leakage of the cell’s contents (Figure 4B).
Conversely, MCRnc cells underwent little physical changes,
presenting only 10% of FSClowSSClow (Figure 4B). Furthermore,
the internalisation of BCG by viable MCRsTnþ cells at 24 h was
markedly increased in relation to the controls (MCRnc;
Supplementary Figure 2, supplementary section), therefore, in
accordance with the observations made for 6 h.
These results present evidence that both BCG internalisation
and loss of cell viability are correlated and both features are
enhanced in cells expressing sTn antigen. Altogether, these
findings suggest that the bacillus acts more efficiently in cells
expressing sTn probably due to its higher internalisation.
DISCUSSION
A significant percentage of high risk of recurrence/progression
bladder tumours, conservatively treated with BCG immunotherapy
after surgery, express cell-proteins yielding the sTn antigen
(Ferreira et al, 2013). Despite the malignant potential of these
tumours (Ferreira et al, 2013) and evidences that sTn expression
may modulate the cell–BCG interaction (Clement et al, 2004;
Julien et al, 2006; Pinho et al, 2007) as well as immune responses
(Gilewski et al, 2007; Julien et al, 2009; Takamiya et al, 2013),
nothing is known about the way patients exhibiting sTn-positive
tumours respond to treatment.
We first observed that treatment outcome was influenced
by age, treatment scheme and tumour multifocallity, as showed
in other reports (Bohle and Bock, 2004; Joudi et al, 2006;
Fernandez-Gomez et al, 2008; Malmstrom et al, 2009; Kohjimoto
et al, 2010; Ajili et al, 2012). To overcome the samples
heterogeneity, these variables were taken into account in multi-
variate analysis models to assess the influence of tumour-associated
glycans in BCG response.
We also found that sTn expression was associated with high-
grade tumours, which is in agreement with our previous
observations (Ferreira et al, 2013). STn expression was also
associated with primary tumours. However, this may result from
fact that the percentage of high-grade tumours was much higher
among primary cases (90%) than in recurrences (67%). Altogether,
these data reinforce the notion that sTn is a surrogate marker of
high-risk bladder cancer.
Furthermore, we report for the first time that bladder
tumours express the sTn-related carbohydrate antigen s6T.
From the structural point of view, s6T may be considered a form
of the sTn antigen masked by a Gal residue O-3 linked to the
GalNAc moiety. To our knowledge, s6T has only been observed
in human cancer cell lines (Marcos et al, 2004; Julien et al, 2006;
Pinho et al, 2007). We also describe that the incubation of tissue
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Figure 2. Effect of sTn and s6T expression in recurrence-free survival (RFS). Kaplan–Meier analysis to evaluate the association between RFS in the
studied patients and: (A) sTn expression; (B) STn plus s6T presence (sTn/S6T). Comparison performed by log-rank test (A: P¼ 0.157; B: P¼ 0.001);
± censored sTn or sTn/s6T-negative tumours; ~ censored sTn or sTn/s6T-negative tumours.
Table 4.Multivariate analysis and risk estimation of sTn and s6T influence
on BCG therapy outcome
HRa 95% CI P value
sTn
Negative 1.0 Referent
Positive 0544 0275–1.076 0.080
sTnþ s6T
Negative 1.0 Referent
Positive 0296 0148–0.594 0.001
Abbreviations: BCG¼Bacillus Calmette-Gue´rin; CI¼ confidence interval; HR¼ hazard ratio.
aAdjusted for age, tumour number and BCG schedule.
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sections with a b-(1-3)-galactosidase removed the O-3-linked
Gal residue exposing the sTn antigen, allowing its detection by
immunohistochemistry with the same antibody used for sTn
without significant time consumption. This approach may now
be applied to estimate s6T expression in other solid tumours.
Studies in vitro studies have shown that s6T expression
influences tumour microenvironment similarly to sTn (Pinho
et al, 2007). Therefore, both antigens were evaluated in the
context of BCG immune response.
STn expression alone or in combination with that of s6T was
associated with lower recurrence rates after BCG. Furthermore,
patients expressing sTn and/or s6T presented longer RFS and these
antigens were found to be independent predictive markers of
reduced recurrence after BCG immunotherapy. Moreover, recur-
rences after treatment displayed a reduced expression of sTn
antigens suggesting that BCG may be more effective against cells
expressing these glycans. Thus, sTn-like O-glycans should be
considered in a biomarker panel directed to predict BCG treatment
outcome.
STn-expressing cells presented enhanced capacity for BCG
adhesion and internalisation and higher BCG-mediated cell death
in vitro. This strongly suggests that sTn expression favours BCG-
mediated elimination of tumour cells, which may, in part, explain
the high correlation between these glycans and treatment response.
The exact mechanism underlying these observations remains
unknown. However, BCG is known to bind fibronectin–a5b1
integrin complexes promoting a rearrangement of cytoskeletal
actin in host cells, which results in the phagocytosis of the
pathogen (Chen et al, 2003; Alexandroff et al, 2010). Clement et al
(2004) described that integrin b1 chains express sTn and that the
antigen enhanced integrin-fibronectin adhesion. Thus, sTn may
contribute to a more efficient binding of the bacillus to tumour
cells and consequently a better response to BCG. The bacillus may
also directly target cells in a fibronectin-independent manner
(Schneider et al, 1994), namely by binding sTn or specific
carbohydrates residues such as a2,6 sialic acids. On the other
hand, sTn is a product of incomplete O-glycosylation of proteins
(Dall’Olio et al, 2012), a reduction in the structural complexity of
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Figure 4. Effect of BCG in the viability of bladder cancer cell lines expressing sTn. (A) The apoptotic status of MCR cell lines was evaluated after
6 h exposure to BCG, by Annexin V staining and flow cytometry analysis. Flow cytometry histograms show MCRnc and MCRsTnþ cells labelled
with Annexin V before (light grey histograms) and after 6 h of BCG treatment (dark grey and open histograms, respectively). MCRsTnþ cells
showed higher Annexin V labelling (MFIMCRnc¼ 2560 to MFIMCRsTnþ ¼ 2640—horizontal arrow) and a higher percentage of cells with strong
Annexin V labelling (4% to 7%—vertical arrow). (B) Analysis of size and granularity of cells exposed 24 h to BCG. Dot plot analysis of BCG-treated
MCRsTnþ revealed a marked decrease of both side-angle light scatter (SSc) and forward-angle light scatter (FSc) signals, which is consistent with
massive cell death. By contrast, BCG treatment resulted in little changes of the dot plot pattern of MCRnc cells. Data are from one representative
assay out of three independent experiments.
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Figure 3. BCG internalisation by bladder cancer cell lines over time. (A) Internalisation of fluorescent-labelled BCG by mock-transduced MCRnc
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sense arrows represent the MFI shift observed after 6 h of BCG internalisation.
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O-glycan may allow the bacillus to bind more efficiently to tumour
cells. The expression of sTn also induces profound morphological
changes in tumour cells (Clement et al, 2004; Pinho et al, 2007)
that may further contribute to the bacillus attachment. A deeper
understanding of these phenomena may provide new insights on
the mechanism of action of BCG and ways to improve the
therapeutics.
The efficiency of BCG therapy among sTn-positive tumours
may also be related with the immunogenic properties of the
antigen (Gilewski et al, 2007; Julien et al, 2009; Takamiya et al,
2013). sTn-based vaccines elicit strong immune responses against
breast, ovarian and colorectal cancers in animal models (Gilewski
et al, 2007; Julien et al, 2009). Still, using BCG as an immunologic
adjuvant was considered essential for the development of both
humoral and cellular immune responses against sTn (Miles et al,
1996; O’Boyle et al, 2006). Similarly, instillations with BCG may be
enhancing immune responses against these tumour-associated
glycans. On the other hand, we observed a higher internalisation of
BCG by sTn-expressing cells. After BCG internalisation, malignant
cells often act as antigen-presenting cells contributing to the
immunologic cascade that leads to tumour clearance (Ratliff, 1992;
Alexandroff et al, 2010). Therefore, one may also hypothesise that
the expression of this particular glycan may increase the
probability of generating BCG antigen-presenting cells in the
tumour niche. Understanding these events may allow developing
alternative carbohydrate-based immunotherapies for bladder
cancer and should be addressed in future studies.
Although this is a retrospective study involving a limited
number of cases, our results strongly suggest that BCG
immunotherapy is efficient against sTn-positive tumours. Even
though we have not determined the exact mechanisms underlying
this event, we demonstrated that BCG adhesion and internalisation
is higher for sTn-positive cells in vitro, further reinforcing tumour
findings.
In conclusion, it has been demonstrated that sTn and s6T
antigens correlated with a better response to this treatment. These
glycans, in association with other BCG response-associated
molecules, may allow the establishment of a predictive panel that
can guide therapeutic decision.
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